Combination therapy for second-line small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two medicines — a chemotherapy called irinotecan liposome and an immunotherapy called ivonescimab — for people whose small cell lung cancer has returned or progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your lung cancer has to be the small cell type and it must have gotten worse after one round of standard chemotherapy (with or without immunotherapy).
- You should be in fairly good health — able to care for yourself and get around (ECOG 0 or 1).
- If you have brain tumors, they must be treated and stable for at least a month, or you must not have any untreated ones.
- You need at least one tumor that can be measured on a scan, and you must be able to give written permission to join.
- You should not have an active autoimmune disease, recent major surgery, or a serious bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—a type of chemotherapy called paclitaxel (in a special micelle formulation, like a tiny carrier) plus an immunotherapy called ivonescimab—for people whose small-cell lung cancer has returned after standard treatment. The goal is to see if this combo can help shrink tumors and slow the cancer's growth.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Hear when a new SCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.